Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study

Yanagimoto, Yoshitomo; Yamashita, Kotaro; Kawabata, Ryohei; Omori, Takeshi; Motoori, Masaaki; Nakahara, Yujiro; Kimura, Yutaka; Furukawa, Haruna; Saito, Takuro; Yamamoto, Kazuyoshi; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Eguchi, Hidetoshi; Doki, Yuichiro

doi:https://doi.org/10.1007/s10120-025-01637-3

Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study

Yanagimoto, Yoshitomo; Yamashita, Kotaro; Kawabata, Ryohei et al.

Gastric Cancer, 2025

アクセス数:10件（2025-08-31 20:57 集計）

固定URL: https://hdl.handle.net/11094/102602

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
GastricCancer	pdf	なし	908 KB		2025.08.29

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study
著者	NRID 1000070645085 1000070645085 著者名 Yanagimoto, Yoshitomo
	NRID 1000020747159 1000020747159 researchmap permalink k-yamashita k-yamashita Scopus Author ID 57191498316 57191498316 著者名 Yamashita, Kotaro
	著者名 Kawabata, Ryohei
	NRID 1000040423181 1000040423181 著者名 Omori, Takeshi
	著者名 Motoori, Masaaki
	著者名 Nakahara, Yujiro
	NRID 1000080716994 1000080716994 著者名 Kimura, Yutaka
	著者名 Furukawa, Haruna
	NRID 1000020646468 1000020646468 researchmap permalink tsaito19 tsaito19 Scopus Author ID 57211629912 57211629912 著者名 Saito, Takuro
	NRID 1000070528637 1000070528637 researchmap permalink kymamoto13 kymamoto13 Scopus Author ID 12764120500 12764120500 著者名 Yamamoto, Kazuyoshi
	NRID 1000050452389 1000050452389 ORCID 0000-0003-2397-1478 0000-0003-2397-1478 researchmap permalink mihogaoka13611 mihogaoka13611 Scopus Author ID 56182761100 56182761100 著者名 Takahashi, Tsuyoshi
	NRID 1000010470197 1000010470197 researchmap permalink krkw krkw Scopus Author ID 7202562410 7202562410 著者名 Kurokawa, Yukinori
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 著者名 Eguchi, Hidetoshi
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
キーワード等	Anamorelin
	Body weight loss
	Cancer cachexia
	Gastric cancer
内容	The version of record of this article, first published in Gastric Cancer, is available online at Publisher’s website: https://doi.org/10.1007/s10120-025-01637-3.
抄録	Background: In 2021, anamorelin, a ghrelin receptor agonist, was approved in Japan for cancer cachexia in select cancers, including gastric cancer. However, evidence regarding its efficacy and predictive factors in patients with gastric cancer remains lacking. Methods: This prospective observational study encompassed 229 patients with unresectable, advanced, or recurrent gastric cancer and cancer cachexia who received anamorelin from 2021 to 2023 at 25 institutions affiliated with Osaka University. Body weight change at 12 weeks was the primary endpoint. Appetite, food intake, treatment compliance, and adverse events comprised the secondary endpoints. Multivariable logistic regression analyses were employed for identifying weight gain predictors. Results: Of the 229 patients (median age, 73 years), 126 completed the 12-week follow-up. The median anamorelin administration duration was 62 days. The mean weight significantly increased from baseline to 4, 8, and 12 weeks (up to + 0.88 kg, p < 0.001). Moreover, appetite and food intake improved. Multivariable analysis identified baseline body mass index (BMI) < 20 kg/m² and neutrophil-to-lymphocyte ratio (NLR) < 4.0 as independent predictors of significant weight gain at 12 weeks. Treatment was generally well tolerated, with a 41% completion rate; 59% of the participants discontinued mainly owing to disease progression. Conclusion: In patients with gastric cancer-related cachexia, anamorelin was associated with significant increases in body weight and improvements in appetite. Lower BMI and lower systemic inflammation (NLR < 4.0) were predictive of better response.
出版者	Springer Science and Business Media LLC
収録物名	Gastric Cancer
刊行年月	2025-07-08
言語	英語
ハンドルURL	https://hdl.handle.net/11094/102602
PISSN	14363291
eISSN	14363305
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1007/s10120-025-01637-3
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Gastric Cancer. 2025
DC.title	Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study
DC.creator	Yanagimoto, Yoshitomo
	Yamashita, Kotaro
	Kawabata, Ryohei
	Omori, Takeshi
	Motoori, Masaaki
	Nakahara, Yujiro
	Kimura, Yutaka
	Furukawa, Haruna
	Saito, Takuro
	Yamamoto, Kazuyoshi
	Takahashi, Tsuyoshi
	Kurokawa, Yukinori
	Eguchi, Hidetoshi
	Doki, Yuichiro
DC.publisher	Springer Science and Business Media LLC
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-07-08
DC.identifier	https://doi.org/10.1007/s10120-025-01637-3
DC.subject	Anamorelin
	Body weight loss
	Cancer cachexia
	Gastric cancer
DC.description	The version of record of this article, first published in Gastric Cancer, is available online at Publisher’s website: https://doi.org/10.1007/s10120-025-01637-3.
DCTERMS.abstract	Background: In 2021, anamorelin, a ghrelin receptor agonist, was approved in Japan for cancer cachexia in select cancers, including gastric cancer. However, evidence regarding its efficacy and predictive factors in patients with gastric cancer remains lacking. Methods: This prospective observational study encompassed 229 patients with unresectable, advanced, or recurrent gastric cancer and cancer cachexia who received anamorelin from 2021 to 2023 at 25 institutions affiliated with Osaka University. Body weight change at 12 weeks was the primary endpoint. Appetite, food intake, treatment compliance, and adverse events comprised the secondary endpoints. Multivariable logistic regression analyses were employed for identifying weight gain predictors. Results: Of the 229 patients (median age, 73 years), 126 completed the 12-week follow-up. The median anamorelin administration duration was 62 days. The mean weight significantly increased from baseline to 4, 8, and 12 weeks (up to + 0.88 kg, p < 0.001). Moreover, appetite and food intake improved. Multivariable analysis identified baseline body mass index (BMI) < 20 kg/m² and neutrophil-to-lymphocyte ratio (NLR) < 4.0 as independent predictors of significant weight gain at 12 weeks. Treatment was generally well tolerated, with a 41% completion rate; 59% of the participants discontinued mainly owing to disease progression. Conclusion: In patients with gastric cancer-related cachexia, anamorelin was associated with significant increases in body weight and improvements in appetite. Lower BMI and lower systemic inflammation (NLR < 4.0) were predictive of better response.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	102602
citation_title	Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study
citation_author	Yanagimoto, Yoshitomo
	Yamashita, Kotaro
	Kawabata, Ryohei
	Omori, Takeshi
	Motoori, Masaaki
	Nakahara, Yujiro
	Kimura, Yutaka
	Furukawa, Haruna
	Saito, Takuro
	Yamamoto, Kazuyoshi
	Takahashi, Tsuyoshi
	Kurokawa, Yukinori
	Eguchi, Hidetoshi
	Doki, Yuichiro
citation_publisher	Springer Science and Business Media LLC
citation_language	英語
citation_date	2025-07-08
citation_journal_title	Gastric Cancer
citation_doi	https://doi.org/10.1007/s10120-025-01637-3
citation_public_url	https://hdl.handle.net/11094/102602

Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study

閲覧可能ファイル

論文情報

論文詳細を表示